Patents Issued in December 20, 2016
  • Azole derivative
    Patent number: 9522914
    Abstract: The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: December 20, 2016
    Assignee: TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Mitsukane Yoshinaga, Takeshi Kuwada, Naoki Miyakoshi, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Youichi Shimazaki
  • Method for preparing an important intermediate of linagliptin
    Patent number: 9522915
    Abstract: The present invention discloses an improved process for preparing an important intermediate of linagliptin. In particular, disclosed are a process for preparing a compound V which is an important intermediate of linagliptin and has the structure V, and an industrial process of preparing linagliptin having excellent chemical and optical purities, which is an inhibitor of dipeptidyl peptidase-4 (DPP-IV), from the compound V. The process employs a phase-transfer catalyst, is high in yield, easy and simple to handle, environmentally friendly, suitable for industrial mass production, and can be implemented by a “one-pot process”.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: December 20, 2016
    Assignee: 2Y-CHEM, LTD.
    Inventors: Yanfeng Zhou, Yong Liu, Xuezhang Wang, Xungui He, Yuan Wang
  • Aadenosine receptor antagonists
    Patent number: 9522916
    Abstract: This invention relates to compounds of formula (I), Wherein R1-R4 are defined in the Specification, their uses in the practice of medicine, their medicinal formulations, their use in medical diagnosis, and their preparation.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: December 20, 2016
    Inventor: Constance Neely Wilson
  • Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
    Patent number: 9522917
    Abstract: Methods to improve hematopoiesis and increase white blood cell counts in subjects and patients using pyrimidine-based inhibitors of Bruton's tyrosine kinase (Btk) are disclosed.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: December 20, 2016
    Assignee: Acerta Pharma B.V.
    Inventors: Raquel Izumi, Francisco Salva, Ahmed Hamdy
  • Pharmaceutical compositions comprising perillyl alcohol derivatives
    Patent number: 9522918
    Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: December 20, 2016
    Assignee: NeOnc Technologies, Inc.
    Inventors: Thomas Chen, Daniel Levin, Satish Pupalli
  • Oxycodone compositions
    Patent number: 9522919
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: December 20, 2016
    Assignees: Purdue Pharma L.P., P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., Rhodes Technologies
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Bromodomain inhibitors and uses thereof
    Patent number: 9522920
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: December 20, 2016
    Assignee: CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Victor S. Gehling, Jean-Christophe Harmange, Michael Charles Hewitt, Yves Leblanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • Photochromic spirooxazine compounds
    Patent number: 9522921
    Abstract: A photochromic dye comprising at least one compound characterized by Formula I:
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: December 20, 2016
    Assignee: Sabic Global Technologies, B.V.
    Inventors: Girish Koripelly, Mohamed Ashraf Moideen, Pradeep Jeevaji Nadkarni, Meghna Markanday
  • Process for the preparation of intermediate for the preparation of oseltamivir phosphate
    Patent number: 9522922
    Abstract: The present invention discloses an economic, simple, azide and aziridine complexity free process for the synthesis of osletamivir phosphate (Tamiflu) by stereospecific amidoalkylation of imidazothiazolone from easily available L-cysteine via Ramberg-Backlund reaction and Sharpless-Reich protocol.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: December 20, 2016
    Assignee: Council of Scientific and Industrial Research
    Inventors: Subhash Prataprao Chavan, Prakash Narsing Chavan
  • Selective BACE1 inhibitors
    Patent number: 9522923
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof, that are inhibitors of BACE.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: December 20, 2016
    Assignee: Eli Lilly and Company
    Inventors: Simon James Richards, Erik James Hembre, Jose Eduardo Lopez, Leonard Larry Winneroski, Jr., Timothy Andrew Woods, Jennifer Anne McMahon
  • Pyridone derivatives as acid secretion inhibitors and process for preparation thereof
    Patent number: 9522924
    Abstract: The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R1, R2 and R3 are independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. R1 is methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, R2 is methyl, methoxy and hydrogen, and R3 is methyl and hydrogen.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: December 20, 2016
    Assignee: Emcure Pharmaceuticals Limited
    Inventors: Mukund Keshav Gurjar, Narendra Kumar Tripathy, Golakchandra Sudarshan Maikap, Rajendra Dagesing Mahale, Tushar Pandurang Khaladkar, Ashok Tukaram Chaudhari, Sanjay Shankar Pawar, Vijay Keshav Kalhapure, Samit Satish Mehta
  • Selective cancer tracking eradicator and the uses thereof
    Patent number: 9522925
    Abstract: The present invention discloses a new modality of photodynamic therapy (PDT) through the design of the present invention's truly dual-functional—PDT and imaging—gadolinium complex (Gd—N) with a molecular formula of: which can target cancer, cells specifically. The present invention provides a PDT drug that can specifically localize on the anionic cell membrane of cancer cells in which its laser-excited photoemission signal can be monitored without triggering the phototoxic generation of reactive oxygen species—singlet oxygen—prior to due excitation. The present invention also provides the use of Gd—N as a tumor selective PDT photosensitizer modality.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: December 20, 2016
    Assignee: Hong Kong Baptist University
    Inventors: Ka-Leung Wong, Wai-Kwok Wong, Rongfeng Lan, Tao Zhang
  • Activators of glucokinase
    Patent number: 9522926
    Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: December 20, 2016
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Feng Tian, Qun Dang, G. Sridhar Prasad, Wenyu Li, Brett C. Bookser, Nicholas Brian Raffaele, Mark D. Erion
  • DOPO derivative flame retardants
    Patent number: 9522927
    Abstract: The present invention relates to novel, halogen-free flame retardant derived from 9,10-Dihydro-9-Oxa-10-Phosphaphenantrene-10-oxide (DOPO). This invention also relates to the use of the halogen free DOPO derived flame retardant in polymers.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: December 20, 2016
    Assignee: Albemarle Corporation
    Inventors: Yu Li Angell, Kimberly M. White, Scott E. Angell, Arthur G. Mack
  • Mannosylated compounds useful for the prevention and the treatment of infectious diseases
    Patent number: 9522928
    Abstract: The present invention relates to new anti-infectious compounds consisting of (i) a polar head having from one to three mannose, dimannose or trimannose moieties, which is coupled through an appropriate linker to (ii) a single lipid chain of at least 17 carbon atoms in length. Pharmaceutical compositions and therapeutic uses thereof are also provided.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: December 20, 2016
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Rachid Baati, Laure Dehuyser, Christopher Mueller, Evelyne Schaeffer, Alain Wagner
  • Non-caloric sweetener
    Patent number: 9522929
    Abstract: Disclosed is a steviol glycoside referred to as rebaudioside D3. Rebaudioside D3 has five ?-D-glucosyl units connected to the aglycone steviol. Also disclosed are methods for producing rebaudioside D3, a UDP-glycosyltransferase fusion enzyme, and methods for producing rebaudioside D and rebaudioside E.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: December 20, 2016
    Assignee: Conagen Inc.
    Inventors: Guohong Mao, Venkata Sai Prakash Chaturvedula, Oliver Yu
  • Chartreusin analogues
    Patent number: 9522930
    Abstract: The present invention relates to novel Chartreusin analogues of formula (I), pharmaceutical compositions comprising the same and to their use for the treatment of cancer and other diseases.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: December 20, 2016
    Assignee: LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE
    Inventors: Christian Hertweck, Hans-Martin Dahse, Nico Ueberschaar, Tom Bretschneider, Kirstin Scherlach, Mikko Metsae-Ketelae
  • Process for the preparation of compounds useful as inhibitors of SGLT-2
    Patent number: 9522931
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: December 20, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kenneth M. Wells, Ronald K. Russell, Xun Li, Shawn Branum, Derek A. Beauchamp, Sumihiro Nomura, Yosuke Matsumura
  • Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
    Patent number: 9522932
    Abstract: The invention is directed to a process for the preparation of substituted threonolactone and substituted threose compounds which are intermediates in the synthesis of phosphonate nucleosides being useful antiviral agents.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: December 20, 2016
    Assignee: K.U. Leuven Research & Development
    Inventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
  • Diagnosis of hereditary spastic paraplegias (HSP) by identification of a mutation in the ZFYVE26 gene or protein
    Patent number: 9522933
    Abstract: The Invention relates to an ex vivo method of diagnosing or predicting a hereditary spastic paraplegias (HSP), in a subject, which method comprises detecting a mutation in the ZFYVE26 gene or protein (spastizin), wherein said mutation is indicative of a hereditary spastic paraplegias (HSP).
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: December 20, 2016
    Assignee: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
    Inventors: Giovanni Stevanin, Sylvain Hanein, Amir Boukhris, Cyril Goizet, Elodie Martin, Alexis Brice
  • Acetatic abiraterone trifluoroacetate and preparation method and application of same
    Patent number: 9522934
    Abstract: Provided are acetaic abiraterone trifluoroacetate, a preparation method and an application of same. The acetaic abiraterone trifluoroacetate is obtained through a salt-forming reaction between acetaic Abiraterone and trifluoroacetic acid. The acetaic abiraterone trifluoroacetate undergoes self-purification through recrystallization, and dissociation and recrystallization are performed on the purified abiraterone acetate trifluoroacetate, so that the obtained acetaic abiraterone has a high purity, a high yield and stable quality, and is capable of meeting the requirement for mass production of acetaic abiraterone.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: December 20, 2016
    Assignees: Shanghai Cdymax Pharmaceuticals Co., Ltd., Jiangsu Cdymax Pharmaceuticals Co., Ltd., Shanghai Acebright Pharmaceuticals Group Co., Ltd.
    Inventors: Xiaoxia An, Chengjun Huang, Fengwang Mao
  • Commands and method of treating cancer via RHO pathway
    Patent number: 9522935
    Abstract: Lanosterol derivatives useful as anti-cancer agent, which can inhibit the growth of lung cancer cells, liver cancer cells, mammary cancer cells, brain cancer cells and pancreatic cancer cells, possibly by acting on the RHO pathway.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: December 20, 2016
    Inventors: Xin Liu, Weidong Xie
  • Engineered transcription activator like effector (TALE) proteins
    Patent number: 9522936
    Abstract: Disclosed herein are methods and compositions for design and use of engineered TALEs.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: December 20, 2016
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • Insecticidal proteins
    Patent number: 9522937
    Abstract: Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins (eHIPs) having toxicity to at least corn rootworm are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different Bacillus thuringiensis (Bt) Cry proteins or a modified Cry proteins an eHIP having activity against corn rootworm is designed. Nucleic acid molecules encoding the novel eHIPs are also provided. Methods of making the eHIPs and methods of using the eHIPs and nucleic acids encoding the eHIPs of the invention, for example in transgenic plants to confer protection from insect damage are also disclosed.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: December 20, 2016
    Assignee: Syngenta Participations AG
    Inventors: Hope Hart, Jeng Shong Chen, Cheryl M. Defontes, Frederick Walters
  • Phl p 5a derivatives having reduced allergeneity and retained T-cell reactivity
    Patent number: 9522938
    Abstract: The present invention relates to the preparation and use of variants of the group 5 allergen of the Pooideae which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with T lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: December 20, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Martin Wald, Oliver Cromwell, Andreas Nandy, Helga Kahlert, Bernhard Weber, Helmut Fiebig
  • Hypoallergenic chimeric proteins belonging to the lipid transfer family of for use in the treatment of allergies
    Patent number: 9522939
    Abstract: The present invention relates to recombinant DNA molecules which encode chimeric polypeptides of differing allergens of Parietaria judaica which can be used for the prevention and treatment of allergies, in particular pollen allergies. Specifically, chimeric polypeptides composed of fragments of the allergens Par j 1 and Par j 2 having hypoallergenic characteristics are described. Methods for producing these recombinant polypeptides in heterologous expression systems are also described. Efficient methods of purifying the chimeric proteins are also described.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: December 20, 2016
    Assignee: Bial Industrial Farmaceutica, S.A.
    Inventors: Juan Andres Asturias, Alberto Martinez Garate, Roberto Gonzales Rioja
  • Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
    Patent number: 9522940
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic lipocalin muteins directed against Glypican-3 (GPC-3). The invention also relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the invention also is directed to pharmaceutical compositions comprising such muteins and practical uses of these lipocalin muteins. In addition, the present invention provides methods of using muteins of human lipocalin 2 (Lcn2 or NGAL) for target-specific delivery of therapeutic moieties or detectable labels to cells expressing GPC-3, and related therapeutic and diagnostic utilization.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: December 20, 2016
    Assignee: Pieris Pharmaceuticals GmbH
    Inventor: Klaus Kirchfield
  • Methods and compositions related to chromatin-associated proteins and other factors
    Patent number: 9522941
    Abstract: Chromatin-associated proteins and other factors and their related methods and compositions are isolated and identified.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: December 20, 2016
    Assignee: Case Western Reserve University
    Inventor: Erik D. Andrulis
  • Analogs of temporin-SHa and uses thereof
    Patent number: 9522942
    Abstract: The present invention relates to novel antimicrobial peptides, to pharmaceutical compositions comprising said peptides, and to the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: December 20, 2016
    Assignees: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), INSTITUT DE RECHERCHE POUR LE DEVELOPMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Ali Ladram, Denis Sereno, Feten Abbassi, Bruno Oury, Mohamed Amiche, Pierre Nicolas
  • Treating human immunodeficiency virus infections
    Patent number: 9522943
    Abstract: Methods and compositions for determining a prognosis for a subject infected with HIV, reducing a risk of an HIV infection, and treating or reducing a risk of developing AIDS are described.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: December 20, 2016
    Assignee: Rhode Island Hospital, A Lifespan-Partner
    Inventors: Michelle Lally, Bharat Ramratnam, Ming Li
  • Peptides of syndecan-1 for inhibit angiogenesis
    Patent number: 9522944
    Abstract: The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: December 20, 2016
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Alan C. Rapraeger, DeannaLee M. Beauvais
  • Long-acting oxyntomodulin variants and methods of producing same
    Patent number: 9522945
    Abstract: This invention is directed to a chorionic gonadotrophin carboxy terminal peptide (CTP) modified dual GLP-1/glucagon receptor agonist, and methods of producing and using the same. In one embodiment, the present invention provides a CTP-modified polypeptide comprising a dual GLP-1/glucagon receptor agonist and at least one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus or carboxy terminus of the agonist.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: December 20, 2016
    Assignee: OPKO BIOLOGICS LTD.
    Inventors: Udi Eyal Eyal Fima, Oren Hershkovitz
  • Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
    Patent number: 9522946
    Abstract: The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: December 20, 2016
    Assignee: Hanmi Science Co., Ltd.
    Inventors: Sung Youb Jung, Myung Hyun Jang, Ling Ai Shen, Young Kyung Park, Young Jin Park, Se Chang Kwon
  • Peptidomimetic macrocycles
    Patent number: 9522947
    Abstract: The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: December 20, 2016
    Assignee: AILERON THERAPEUTICS, INC.
    Inventors: Noriyuki Kawahata, Vincent Guerlavais, Manoj Samant
  • GP100-specific T cell receptors and related materials and methods of use
    Patent number: 9522948
    Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: December 20, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
  • Fusion protein for antagonizing angiogenesis inducible factors and uses thereof
    Patent number: 9522949
    Abstract: The present invention relates to angiogenesis-inhibitory fusion proteins and use thereof. Particularly, the present invention provides fusion proteins inhibiting a plurality of angiogenic factors. More particularly, the present invention relates to the fusion proteins of VEGF receptor and FGF receptor and their applications in the treatment of angiogenesis related diseases.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 20, 2016
    Assignee: YANTAI RC BIOTECHNOLOGIES, LTD.
    Inventors: Jianmin Fang, Dong Li
  • Oxidant resistant apolipoprotein A-1 and mimetic peptides
    Patent number: 9522950
    Abstract: A purified polypeptide includes an ApoA1 mimetic or fragment thereof that are resistant to oxidation.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: December 20, 2016
    Assignee: The Cleveland Clinic Foundation
    Inventors: Jonathan D. Smith, Stanley L. Hazen
  • Fibronectin binding domains with reduced immunogenicity
    Patent number: 9522951
    Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: December 20, 2016
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jonathan Davis, Dasa Lipovsek, Ray Camphausen
  • Polypeptide binding to annexin A1 and use thereof
    Patent number: 9522952
    Abstract: A polypeptide binding to Annexin A1, an antagonist against Annexin A1 including the polypeptide, an anti-Annexin A1 antibody including the polypeptide or an antigen-binding fragment thereof, and methods of preventing, treating and/or diagnosing a disease, including administering the antagonist and/or the antibody or an antigen-binding fragment thereof to a subject.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: December 20, 2016
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jieun Han, Jung Min Kim, Jae Il Lee
  • Low acidic species compositions and methods for producing and using the same
    Patent number: 9522953
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 20, 2016
    Assignee: ABBVIE, INC.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Anti-LRP5 antibodies and methods of use
    Patent number: 9522954
    Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: December 20, 2016
    Assignee: GENENTECH, INC.
    Inventors: Yan Wu, Weilan Ye, Jeremy Bryant Burton, Cecilia Chiu
  • Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
    Patent number: 9522955
    Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: December 20, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven A. Rosenberg, Dhanalakshmi Chinnasamy
  • Combination therapy using anti-EGFR and anti-HER2 antibodies
    Patent number: 9522956
    Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: December 20, 2016
    Assignee: L'Institut National de la Sante et de la Recherche Medicale
    Inventors: Stephen D. Gillies, David Azria, Christel Larbouret, André Pelegrin
  • Method of treating an inflammatory condition by administering toll-like 3 receptor antagonists
    Patent number: 9522957
    Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: December 20, 2016
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Raymond Sweet, Fang Teng, Alexey Teplyakov, Sheng-Jiun Wu
  • Cancer targeted innate immunity
    Patent number: 9522958
    Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: December 20, 2016
    Assignee: University of Southern California
    Inventors: Alan L. Epstein, Leslie A. Khawli
  • Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
    Patent number: 9522959
    Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: December 20, 2016
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, David M. Goldenberg
  • Multispecific antibodies
    Patent number: 9522960
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: December 20, 2016
    Assignee: Genentech, Inc.
    Inventors: Jenny M. Bostrom, Germaine Fuh
  • Protein complexes and methods of manufacturing bispecific antibodies using the protein complexes
    Patent number: 9522961
    Abstract: A protein complex comprising (i) a first fusion protein comprising (a) a first polypeptide that comprises a first antigen-binding site and (b) a first binding protein linked to a terminus of the first polypeptide; and (ii) a second fusion protein comprising (a) a second polypeptide that comprises a second antigen-binding site and (b) a second binding protein linked to a terminus of the second polypeptide, wherein the protein complex comprises an amino acid sequence that enables cleavage between the first polypeptide and the first binding protein, and/or between the second polypeptide and the second binding protein, as well as a method for preparing a bi-specific antibody and related methods and compositions.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: December 20, 2016
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jung-wook Lee, Min-Kyung Kim, Seon-hui Shim, Jae-il Lee
  • Peptides, conjugates and method for increasing immunogenicity of a vaccine
    Patent number: 9522962
    Abstract: The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL (residues 383-390 of SEQ ID NO: 3) for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: December 20, 2016
    Assignees: Academisch Ziekenhuis Leiden h.o.d.n. LUMC, Stichting voor de Technische Wetenschappen
    Inventors: Ferdinand Antonius Ossendorp, Cornelis Joseph Maria Melief, Jan Wouter Drijfhout
  • Dissolution of oxidized cellulose
    Patent number: 9522963
    Abstract: A process for dissolving modified cellulose is disclosed. The process includes contacting modified cellulose with a solvent in a mixture to form swelled modified cellulose and then contacting the mixture with a salt to dissolve the swelled modified cellulose.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: December 20, 2016
    Assignee: Covidien LP
    Inventors: Valentino J. Tramontano, Joshua Kennedy, Sajida Farooqi, Phillip Blaskovich, Rachit Ohri, Daniel S. Costa